Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer — Stella

Home/Ovarian High Grade Serous Adenocarcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Ovarian High Grade Serous Adenocarcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Key details

Phase

Safety & dosing

Sponsor

Emory University

Collaborators

National Cancer Institute (NCI)

Enrollment target

~28 participants

Started

November 2023

Primary completion

June 2026

Age range

18 Years and older

Sex

Female only

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.